Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Jianxin Fund has a significant holding in Tiger Med through the Jianxin CSI Innovative Drug Industry ETF (159835), which increased its stake by 34,700 shares in the fourth quarter, holding a total of 127,500 shares, representing 2.88% of the fund's net value [2][5]. - The ETF has generated a floating profit of approximately 323,800 CNY today and 413,100 CNY during the three-day increase [2][5]. - The Jianxin CSI Innovative Drug Industry ETF was established on March 11, 2021, with a current size of 251 million CNY. Year-to-date, it has experienced a loss of 6.97%, ranking 4791 out of 5563 in its category, while it has gained 7.64% over the past year, ranking 3433 out of 4429 [2][5]. Fund Manager Information - The fund manager of the Jianxin CSI Innovative Drug Industry ETF is Gong Jiajia, who has been in the position for 7 years and 36 days. The total asset size of the fund is 1.867 billion CNY, with the best return during the tenure being 44.21% and the worst being -58.77% [3][6][7].
泰格医药股价涨5%,建信基金旗下1只基金重仓,持有12.75万股浮盈赚取32.38万元